Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. . Lancet 2022 Jan 27. pii: S0140-6736(22)00101.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet 2022 Jan 27. pii: S0140-6736(22)00101.
PMID: 35093205